Table 5 HPV incidence in males participating in circumcision clinical trials
| Author | Area, subjects | Study design | HPV test | HPV incident casesc and ratesd for type-specific genotypes per 100 PYs | Proportions of type-specific incident infections at 24-month follow-up | Risk Ratio (RR) and 95% CI† for HR* and multiple infections | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Serwadda et al., 2010 [59] | Rakai district, uncircumcised HIV positive men aged 15-49 years; 103 men in intervention group and 107 men in control group | Randomized controlled trial | Roche HPV linear array |
At 24 months HR-HPV incident casesc Intervention group, 42 cases Control group, 57 cases Multiple infectionincident cases c Intervention group, 9.9 cases Control group, 24.7 cases | Incident proportions |
At 24 months RR for HR-HPV types = 0.74 (0.54-1.01) RR for multiple infection = 0.04 (0.19-0.84). | ||||
|
Interventiond (%) |
Controld (%) | |||||||||
|
HPV 16 HPV 18 HPV 45 HPV 51 HPV 52 |
5.8 4.3 4.1 5.4 10.1 |
14.9 11.1 10.3 13.9 8.2 | ||||||||
| Gray, et al. 2010 [60] | Rakai district, uncircumcised HIV negative men aged 15-49 years; 441 men in intervention and 399 men in control group | Randomized controlled trial | Roche HPV linear array |
At 24 months HR-HPV incident cases c Intervention group, 19.7 cases Control group, 29.4 cases Multiple infection incident cases c Intervention group, 6.7 cases Control group, 14.8 cases Type specific incidence rates d |
At 24 months RR for HR-HPV types = 0.67 (0.51-0.89) RR for multiple infections = 0.45 (0.28-0.73) | |||||
| Intervention | Control | |||||||||
| Incidence/100 PYs | ||||||||||
|
HPV 16 HPV 18 HPV 45 HPV 51 HPV 52 |
3.6 1.6 1.6 4.0 1.6 |
4.8 5.3 2.4 5.3 3.6 | ||||||||
